Home/ArriVent Biopharma/Stuart Lutzker, MD, PhD

Stuart Lutzker, MD, PhD

President, Head of Research & Development, Co-founder

Therapeutic Areas

Drug	Indication	Phase
Firmonertinib	1L NSCLC with EGFR Exon 20 Insertion Mutations	Phase 3
Firmonertinib + SHP2 inhibitor	2L+ NSCLC with EGFR Classical Mutations	Phase 1
ARR-217	Gastrointestinal (GI) Tumors	Preclinical
ARR-002	Solid Tumors	Discovery
ARR-421	Solid Tumors	Discovery
ARR-173	Solid Tumors	Discovery